Journal of Hepatocellular Carcinoma最新文献

{"title":"Retrospective Multicentre Real-Life Study Evaluating the Efficacy of Atezolizumab Combined with Bevacizumab for the Treatment of Metastatic Hepatocellular Carcinoma: HIREAL Study.","authors":"Jean-Baptiste Barbe-Richaud, Fabien Moinard-Butot, Stéphanie Husson-Wetzel, Marion Bolliet, Pascale Chiappa, Christine Belletier, Mathieu Ribeiro, Elodie Poprawa, Cécile Bigot, Armand Abergel, Meher Ben Abdelghani","doi":"10.2147/JHC.S521130","DOIUrl":"10.2147/JHC.S521130","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most common hepatic malignancy and is one of the most prevalent cancers worldwide. The prognosis of late-stage HCC remains poor. The ImBrave 150 trial successfully demonstrated that overall survival (OS) and progression-free survival (PFS) was improved among patients treated with atezolizumab combined with bevacizumab (AB) compared with patients treated with sorafenib. Real-world data are essential to assess the safety and efficacy of new therapies in HCC, given patients' fragility and the heterogeneity of underlying liver diseases.</p><p><strong>Objective: </strong>The primary objective of this study was to evaluate the OS and PFS of patients with locally advanced or metastatic HCC treated with atezolizumab combined with bevacizumab. The secondary objective was to conduct subgroup analyses to further examine how the effects of the combination treatment differ based on Child‒Pugh scores, prior local treatment, and alpha-fetoprotein (AFP) levels.</p><p><strong>Methods: </strong>We conducted a multicentric retrospective study. All patients with confirmed locally advanced or metastatic HCC treated with atezolizumab combined with bevacizumab between January 2021 and December 2023 were included.</p><p><strong>Results: </strong>Seventy patients were included. A total of 76% presented with cirrhosis, among which 85% had Child‒Pugh class A cirrhosis. The cirrhosis cases were mostly nonviral (85.7%). The median OS was 19 months (95% CI: 15-NA), and the median PFS was 6.7 months (95% CI: 4.7-14.2 months). The secondary analysis revealed a statistically significant difference in OS between patients with Child‒Pugh class A cirrhosis and those with Child‒Pugh class B cirrhosis, with median OS durations of 18.9 months (95% CI: 16.9-NA) and 6.0 months (95% CI: 1.5-NA), respectively (p = 0.03). However, the retrospective design and the lack of a control group represent important limitations.</p><p><strong>Conclusion: </strong>Our real-life study yielded OS and PFS durations similar to those reported in the ImBrave 150 trial.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1279-1286"},"PeriodicalIF":4.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Prediction of a Rare and Highly Aggressive Subtype of Hepatocellular Carcinoma Based on Multimodal Imaging and Clinical Indicators.","authors":"Keke Chen, Yuli Zhu, Han Liu, Minying Deng, Wentao Kong, Wenping Wang","doi":"10.2147/JHC.S533963","DOIUrl":"10.2147/JHC.S533963","url":null,"abstract":"<p><strong>Purpose: </strong>To develop and validate a reliable preoperative non-invasive diagnostic model for dual-phenotype hepatocellular carcinoma (DPHCC) by integrating multimodal imaging and clinical indicators, thereby facilitating clinical decision-making.</p><p><strong>Patients and methods: </strong>222 pathologically confirmed patients (61 with DPHCC, 161 with non-DPHCC) were retrospectively enrolled in this study and randomly assigned to training and validation cohorts in an 8:2 ratio. Serological and multimodal imaging characteristics were analyzed. Univariate and multivariate logistic regression analyses identified independent DPHCC predictors and built a nomogram. Model performance and clinical utility were assessed by receiver operating characteristic (ROC) and decision curve analysis (DCA) curve respectively. The calibration curve was used to verify the model. Recurrence-free survival (RFS) was assessed using Kaplan-Meier and Log rank tests.</p><p><strong>Results: </strong>In multivariate analysis, age (OR=0.91; P < 0.001), LDH (OR=1.03; P=0.002), PT (OR=0.14; P < 0.001), AFP (OR=4.04; P=0.019), Adler grade (OR=0.17; P=0.037), non-enhancing area (OR=8.30; P=0.004), arterial phase hyperenhancement (OR=0.12; P=0.015) and enhancing capsule (OR=0.32; P=0.04) were independent predictors of DPHCC. The nomogram achieved a robust predictive performance with C-index (0.92 vs 0.87) and accuracy (0.87 vs 0.86) in the training and validation cohorts. In addition, the calibration curve and DCA also showed good model performance. DPHCC patients had significantly lower RFS than non-DPHCC patients (P = 0.037).</p><p><strong>Conclusion: </strong>A nomogram was established for non-invasive prediction of DPHCC risk utilizing multimodal imaging combined with clinical indicators to help achieve personalized treatment.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1253-1266"},"PeriodicalIF":4.2,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of AFP-Negative Patients with Advanced HCC: A Propensity-Matched Analysis from a Retrospective Cohort Study.","authors":"Xiufeng Liu, Lijun Zhuang, Fan Yang, Ping Liu, Zhaojun Xia, Ying Guo, Pingping Dong, Chao Chen, Zixiong Li","doi":"10.2147/JHC.S527332","DOIUrl":"10.2147/JHC.S527332","url":null,"abstract":"<p><strong>Introduction: </strong>AFP positivity (≥20 ng/mL) is often used as one of the diagnostic criteria for HCC. The aim of this study is to analyze the prognosis of advanced HCC with negative (<20 ng/mL) AFP at baseline following systemic drug treatment.</p><p><strong>Methods: </strong>In this study, 91 patients with AFP-negative advanced HCC who received systemic drug treatment in Nanjing Jinling Hospital from February 2011 to September 2023 were collected, and 213 patients with AFP-positive advanced HCC were collected as the control group. A propensity score model was used to adjust for potential confounding variables. Cox regression analysis was used to clarify the differences of prognosis in subgroups for HCC patients.</p><p><strong>Results: </strong>Following propensity score matching with 1:2 ratio, 90 HCC patients from Group A (AFP-negative) and 180 from Group B (AFP-positive) were chosen to participate in the final analysis set. The OS of AFP-negative HCC patients was extended by 13.5 months compared to AFP-positive HCC patients. Within the AFP-negative HCC group, the top-ranked first-line treatment options were TKIs combo ICIs (mPFS = 9.5m, mOS = 37.1m), chemotherapy combo ICIs (mPFS = 8.1m, mOS = 15.5m), and TKIs (mPFS = 5.6m, mOS = 28.2m). Subgroup analysis indicated that among AFP-negative HCC patients, those without PVTT or with HBV DNA <50lU/mL had longer survival time. For HCC patients who opted for TKIs combo ICIs as their first-line treatment and then switched to TKIs alone for second-line treatment, the mOS and 95% CI were 30.7 (24.8-NA) months.</p><p><strong>Conclusion: </strong>The survival time of AFP-negative HCC patients was significantly longer than that of AFP positive HCC patients. Patients with no PVTT or HBV DNA <50lU/mL have relatively better efficacy of systemic drug therapy. With the AFP-negative HCC patients, TKIs combo ICIs are preferentially recommended for the first-line therapy, and TKIs are used for the second-line therapy after progression.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1241-1252"},"PeriodicalIF":4.2,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12212435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Computed Tomography and Ultrasound-Guided Radiofrequency Ablation for Recurrent Subdiaphragmatic Hepatocellular Carcinoma After Resection.","authors":"Hao-Yun Liu, Chih-Yang Hsiao, Rey-Heng Hu, Po-Chin Liang, Chih-Horng Wu","doi":"10.2147/JHC.S524399","DOIUrl":"10.2147/JHC.S524399","url":null,"abstract":"<p><strong>Objective: </strong>Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide. Although surgical resection and liver transplantation are considered curative, recurrence is common, especially after hepatectomy. Radiofrequency ablation (RFA) offers a minimally invasive alternative for treating recurrent HCC. However, its efficacy is influenced by tumor location and imaging guidance. This study aims to compare the outcomes of CT-guided and US-guided RFA in patients with single small recurrent HCCs located in the subdiaphragmatic region after hepatectomy.</p><p><strong>Methods: </strong>In this retrospective single-center study, we included patients who received RFA for recurrent HCC following curative hepatectomy between 2008 and 2020. Patients were categorized into CT-guided or US-guided RFA groups. RFA was performed by experienced interventional radiologists, and follow-up imaging was conducted every 3-6 months to assess recurrence. The primary outcome was recurrence-free survival (RFS), and the secondary outcome was overall survival (OS).</p><p><strong>Results: </strong>In this study, 59 and 32 patients with subdiaphragmatic lesions underwent CT-guided- and US-guided RFA, respectively, for single recurrent HCC. The CT-guided group showed larger tumor size, lower recurrence rates, and significantly better RFS in Kaplan-Meier analysis compared to the US-guided group (49.5 months vs 35.7 months, p value= 0.042). Multivariate analysis confirmed a superior RFS hazard ratio (HR=0.551) for CT-guided RFA, although the overall survival showed no significant difference. Major complications were absent in both groups.</p><p><strong>Conclusion: </strong>CT-guided RFA provides improved RFS for subdiaphragmatic recurrent HCC, highlighting its potential as a preferred technique for challenging anatomical locations. Further multicenter prospective studies are necessary to validate these findings and assess the long-term survival outcomes.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1231-1240"},"PeriodicalIF":4.2,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12212096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Outcomes of Systemic Therapies for Infiltrative Hepatocellular Carcinoma.","authors":"Po-Yi Chen, Chih-Kai Chang, Bang-Bin Chen, Chih-Hung Hsu, Ann-Lii Cheng, Yu-Yun Shao","doi":"10.2147/JHC.S528897","DOIUrl":"10.2147/JHC.S528897","url":null,"abstract":"<p><strong>Purpose: </strong>Outcomes in the treatment of unresectable infiltrative hepatocellular carcinoma (HCC) are poorly understood, and infiltrative HCC is generally underrepresented in clinical trials. The present study explored outcomes associated with the treatment of infiltrative HCC with various systemic therapies.</p><p><strong>Patients and methods: </strong>We enrolled all patients with Barcelona Clinic Liver Cancer stage C infiltrative or multinodular HCC who received first-line systemic therapy between January 2015 and December 2021 at a single center. We compared baseline characteristics and treatment outcomes for the two HCC subtypes.</p><p><strong>Results: </strong>In total, 260 patients were enrolled, 128 (49.2%) of whom had infiltrative HCC. Patients with infiltrative HCC were more likely to have macrovascular invasion (91.4% vs 68.2%, <i>p</i> < 0.001) but less likely to have extrahepatic spread (32.0% vs 54.5%, <i>p</i> < 0.001) than patients with multinodular HCC. In patients who received multikinase inhibitors alone, the time to treatment failure (TTF) and overall survival (OS) were similar for the 2 HCC subtypes. In patients who received immune checkpoint inhibitor (ICI)-based therapy, multivariate analyses revealed that infiltrative HCC was associated with shorter TTF (HR: 4.07, 95% CI: 2.13-7.79, <i>p</i> < 0.001) and poorer OS (HR: 3.27, 95% CI: 1.76-6.11, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>In patients receiving ICI-based therapy for HCC, infiltrative HCC was associated with poorer outcomes.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1221-1229"},"PeriodicalIF":4.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Robotic Surgery in Hepatocellular Carcinoma.","authors":"Pei-Heng Li, Zhao-Wei Ding, Yong-Qing Ye","doi":"10.2147/JHC.S515987","DOIUrl":"10.2147/JHC.S515987","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) has a lot of possible treatment strategies. At present, the clinical treatment of Hepatocellular carcinoma is mainly surgical treatment, according to the different conditions of patients, there are also differences in the choice of surgical methods. Open liver resection, laparoscopic liver resection, and robotic liver resection are some of the suitable treatment options. In this paper, the current advantages, limitations, and future of robotic surgery in HCC are reviewed and analyzed for clinicians' reference.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1217-1220"},"PeriodicalIF":4.2,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy.","authors":"Xin Zheng, Kun Qian","doi":"10.2147/JHC.S520430","DOIUrl":"10.2147/JHC.S520430","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with apatinib and camrelizumab in patients with recurrent hepatocellular carcinoma (HCC) following hepatectomy.</p><p><strong>Methods: </strong>From July 2020 to December 2024, consecutive medical records of recurrent HCC patients treated with HAIC plus apatinib/camrelizumab were retrospectively reviewed. Key outcomes, including overall survival (OS), progression-free survival (PFS), therapeutic response, and treatment-related complications, were evaluated.</p><p><strong>Results: </strong>The study was followed up until January 31, 2025, with a median follow-up duration of 11 months (range: 2-26 months). Among the 110 eligible recurrent HCC patients (91 males and 19 females), 62 deaths were recorded. The objective response rate (ORR) was 31.8%, and the disease control rate (DCR) was 87.3%. The median OS was 14 months (95% CI: 12.9-15.1 months), with multivariable analysis identifying vascular invasion as an independent prognostic factor for OS. The median PFS was 7 months (95% CI: 5.3-8.7 months), and the platelet-to-lymphocyte ratio was found to be an independent prognostic factor for PFS. All adverse events were manageable, and no treatment-related deaths occurred.</p><p><strong>Conclusion: </strong>HAIC combined with apatinib/camrelizumab is effective and safe in the treatment of recurrent HCC after hepatectomy, which may be a promising treatment for recurrent HCC.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1205-1215"},"PeriodicalIF":4.2,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Situ Vaccination with Poly-ICLC Combined with Systemic Nivolumab for the Treatment of Unresectable Hepatocellular Carcinoma.","authors":"Ja-Der Liang, Po-Chin Liang, Chia-Tung Shun, Chien-Hung Chen, Yao-Ming Wu, Yu-Chen Hsu, Ying-Te Lee, Pei-Ming Yang, Guan-Tarn Huang, Andres M Salazar, Hsuan-Shu Lee, Jin-Chuan Sheu, Meng-Tzu Weng","doi":"10.2147/JHC.S520710","DOIUrl":"10.2147/JHC.S520710","url":null,"abstract":"<p><strong>Purpose: </strong>Unresectable hepatocellular carcinoma (HCC) presents significant therapeutic challenges. While immune checkpoint inhibitors (ICIs) are part of the current standard of care, combining poly-ICLC as an in situ vaccination with an ICI may enhance treatment efficacy. The study investigated the safety and therapeutic effects of combining poly-ICLC with nivolumab, an ICI, in patients with unresectable HCC.</p><p><strong>Patients and methods: </strong>Patients with unresectable HCC were enrolled to receive intratumoral and intramuscular poly-ICLC injections along in combination with nivolumab infusions. The primary endpoint was safety, and secondary endpoints included objective response as measured by mRECIST and changes in serum alpha-fetoprotein (AFP) levels. Gene expression profiling, pathway analysis, and immune cell type deconvolution were conducted using NanoString GeoMx Digital Spatial Profiling.</p><p><strong>Results: </strong>Four patients were enrolled. The combination therapy was safe and well-tolerated. Among them, one patient achieved a complete response (CR), and another achieved a partial response (PR). Both responders showed significant declines in serum AFP levels. Notably, the patient with CR showed eradication of cancerous component of the portal vein thrombus, and an abscopal effect was observed in the patient with PR. Gene analysis indicated that interferon-gamma signaling was the most enriched pathway in tumors of the responders.</p><p><strong>Conclusion: </strong>This combination therapy was safe and effective, with two out of four patients demonstrating objective responses. These preliminary findings warrant further investigation into larger clinical cohorts.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1191-1204"},"PeriodicalIF":4.2,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravoxel Incoherent Motion Improves the Accuracy of Preoperative Prediction of Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma.","authors":"Min Li, Ge Zhang, Jing Li, Yufan Ren, Xuan Jin, Qiying Ke, Congyue Guo, Jiaqi Lv, Haojun Lu, Yongzhou Xu, Wen Liang, Xianyue Quan, Xinming Li","doi":"10.2147/JHC.S519223","DOIUrl":"10.2147/JHC.S519223","url":null,"abstract":"<p><strong>Purpose: </strong>Hepatocellular carcinoma (HCC) with vessels encapsulating tumor clusters (VETC) pattern presents a higher risk of recurrence and metastasis, and the unique vascular structure of the VETC pattern may affect the perfusion and diffusion, and the effect that can be captured by intravoxel incoherent motion (IVIM). Therefore, this study used preoperative IVIM to predict VETC pattern in HCC and performed preoperative noninvasive recurrence risk stratification.</p><p><strong>Patients and methods: </strong>Patients with suspicious HCC were included prospectively. Two radiologists independently evaluated radiologic features and measured apparent diffusion coefficient (ADC), true diffusion coefficient (<i>D</i>), pseudo-diffusion coefficient (<i>D</i>*), and pseudo-diffusion fraction (<i>f</i>). Logistic regression analyses were used to identify the predictors associated with the VETC pattern. Receiver operating characteristic (ROC) curve analyses were conducted to assess the predictive performance. Recurrence-free survival was evaluated using the Kaplan-Meier analysis and the Log rank test.</p><p><strong>Results: </strong>The consecutive cohort included 116 patients (mean age, 55 years ± 11, 94 men). Twenty-nine of the 116 HCC (25.0%) were VETC HCC. The <i>f</i> value (odds ratio [OR], 0.791; p < 0.001), serum α-fetoprotein level (>400 ng/mL) (OR, 2.962; p = 0.042), and intratumor necrosis (OR, 6.022; p = 0.015) were independent predictors of the VETC pattern. These characteristics were used to construct the combined model with area under the ROC curve of 0.854. Additionally, adding the <i>f</i> value to the conventional imaging-clinical model substantially improved its predictive performance (p < 0.001). Moreover, patients with the combined model classified as VETC HCC also had a higher risk of early recurrence than those with non-VETC HCC (p < 0.001).</p><p><strong>Conclusion: </strong>IVIM enhances the accuracy of preoperative prediction of the VETC pattern and provides preoperative noninvasive risk stratification for HCC recurrence.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1177-1190"},"PeriodicalIF":4.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12168965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Recurrence of Hepatocellular Carcinoma in Patients without Microscopic Vascular Invasion: Clinicopathological Characteristics and Risk Factors.","authors":"Hanh Thi Tuyet Ngo, Duy Duc Nguyen, Minh-Xuan Dang, Thao Thi Phuong Doan, Truc Thanh Thai","doi":"10.2147/JHC.S524683","DOIUrl":"10.2147/JHC.S524683","url":null,"abstract":"<p><strong>Purpose: </strong>Early recurrence of hepatocellular carcinoma (HCC) is not uniformly associated with microscopic vascular invasion (MVI). This study aims to identify the clinical and pathological factors associated with early recurrence in HCC patients without MVI.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on 69 patients who underwent hepatectomy for HCC at the University Medical Center Ho Chi Minh city. All patients were microscopically confirmed as MVI-negative. Clinical and subclinical data, along with tumor recurrence within 24 months post-surgery were collected. Microscopic features of both tumor and non-tumor liver tissue were assessed using Hematoxylin-Eosin-stained slides.</p><p><strong>Results: </strong>The majority of patients were male (78.3%) and had cirrhosis (72.5%). The early recurrence rate was 31.9%, with most recurrences occurring between 6- and 18-month post-surgery. Independent factors for early tumor recurrence included preoperative treatment with Transarterial Chemoembolization (TACE) or Radiofrequency Ablation (RFA) (HR = 8.63, 95% CI = 1.45-51.38), tumor size > 5 cm (HR = 3.82, 95% CI = 1.17-12.42), and HCV infection (HR = 4.61, 95% CI = 1.41-15.1).</p><p><strong>Conclusion: </strong>The pathogenesis and pattern of early tumor recurrence in MVI-negative HCC differ from that in MVI-positive cases. Identifying risk factors, such as HCV infection, tumor size, and preoperative locoregional therapy, may aid in optimizing treatment strategies and postoperative surveillance.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1167-1175"},"PeriodicalIF":4.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12168972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}